Skip to main content
news
REUTERS/Tingshu Wang

Cooley, CYL & Partners and DeHeng Law Offices have advised China’s Asymchem Laboratories on its HK$6.85 billion ($878 million) secondary listing in Hong Kong, with Latham & Watkins and JunHe representing the joint sponsors.

This is believed to be the biggest healthcare IPO in Hong Kong this year. The company has been listed on the Shenzhen Stock Exchange since 2016.

Asymchem is a Chinese contract development manufacturing organisation (CDMO) serving the global pharmaceutical industry. According to Frost & Sullivan, it is the world’s fifth-largest drug substance CDMO by revenue, and the largest China-based commercial stage chemical drug CDMO.

The Cooley team was led by partners Yiming Liu and Michael Yu.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

SAM, Trilegal, Sidley, W&C act on $415 mln Brookfield REIT QIP

by Nimitt Dixit |

Shardul Amarchand Mangaldas & Co and Sidley Austin have advised their longstanding client Brookfield India Real Estate Trust (BIRET) on its $415 million equity offering through a qualified institutional placement of shares – the only QIP by an Indian REIT in 2024.

Deals

NRF advises Carlsberg on $744 mln South Asia acquisition

by Asian Legal Business《亚洲法律杂志》 |

Global law firm Norton Rose Fulbright has advised Denmark’s Carlsberg Breweries on its $744 million acquisition of the remaining 33.33 percent stake in its Indian and Nepalese operations from partner CSAPL.

Deals

SAM, HSF, CAM guide Jubilant Bhartia Group's $1 bln Coca-Cola deal

by Nimitt Dixit |

Indian law firm Shardul Amarchand Mangaldas & Co. and international law firm Herbert Smith Freehills have advised Jubilant Bhartia Group on its agreement with The Coca-Cola Company to acquire a 40 percent stake in Hindustan Coca-Cola Holdings for over $1 billion.